4.0 Article

Implementation of a Pilot Study to Analyze Circulating Tumor DNA in Early-Stage Lung Cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer

Ning Li et al.

Summary: This study found that monitoring ctDNA before and after surgery in operable non-small cell lung cancer patients is associated with inferior recurrence-free survival and overall survival. Serial ctDNA detection can identify disease recurrence earlier than routine radiologic imaging. ctDNA analysis can detect minimal residual disease in resectable lung cancer patients, facilitating early intervention.

CANCER (2022)

Article Oncology

Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis

Meichen Li et al.

Summary: Adjuvant EGFR tyrosine kinase inhibitors significantly improved disease-free survival and nonsignificantly improved overall survival in resected EGFR-mutated NSCLC. Different treatment regimes, treatment duration, tumor stage, and EGFR mutation type may impact the efficacy of EGFR inhibitors in these post-surgery patients.

FUTURE ONCOLOGY (2022)

Article Oncology

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

D. Gale et al.

Summary: Detection of ctDNA using sensitive patient-specific assays after initial treatment has the potential to identify early-stage NSCLC patients who may benefit from further therapeutic intervention.

ANNALS OF ONCOLOGY (2022)

Article Oncology

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer

Jia-Tao Zhang et al.

Summary: This study confirms the prognostic value of MRD detection in patients with NSCLC after definitive surgery, especially in those with longitudinal undetectable MRD, regardless of stage and adjuvant therapy. The risk of developing detectable MRD decreases stepwise after 18 months since landmark detection.

CANCER DISCOVERY (2022)

Article Medicine, General & Internal

Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice

Manuel R. Teixeira et al.

Summary: Next-generation sequencing (NGS) is widely used in clinical oncology for diagnosis, prognosis, and therapeutic guidance. In the context of lung cancer and rare tumors, it is important to address multiple quality control checkpoints and improve communication between clinicians and laboratory support. NGS panels are recommended for comprehensive genomic profiling in rare tumors. Multidisciplinary tumor boards are essential for tailoring the best strategy for each patient.

ACTA MEDICA PORTUGUESA (2022)

Review Oncology

The epidemiology of lung cancer

Patricia M. de Groot et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2018)

Article Oncology

The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA

Sonya Parpart-Li et al.

CLINICAL CANCER RESEARCH (2017)

Article Multidisciplinary Sciences

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Christopher Abbosh et al.

NATURE (2017)

Article Multidisciplinary Sciences

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing

Inga Medina Diaz et al.

PLOS ONE (2016)

Article Medical Laboratory Technology

Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA

Patricia Valda Toro et al.

CLINICAL BIOCHEMISTRY (2015)

Review Medical Laboratory Technology

Circulating cell free DNA: Preanalytical considerations

Safia El Messaoudi et al.

CLINICA CHIMICA ACTA (2013)

Review Oncology

Liquid biopsy: monitoring cancer-genetics in the blood

Emily Crowley et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2013)

Review Oncology

The State of Molecular Biomarkers for the Early Detection of Lung Cancer

Mohamed Hassanein et al.

CANCER PREVENTION RESEARCH (2012)

Article Oncology

Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group

Jean-Pierre Pignon et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Letter Medical Laboratory Technology

Effects of blood-processing protocols on cell-free DNA quantification in plasma

DW Swinkels et al.

CLINICAL CHEMISTRY (2003)